Onkologie. 2011:5(3):169-174

Hormonal treatment of breast cancer pacients from the viewpoint of the gynecologist

Marie Bendová
Gynekologicko-porodnická klinika 3. LF UK a FNKV, Praha

Author describes hormonal treatment of breast cancer pacients and review gynaecological care from prevention and diagnostics to

monitoring of the first line hormonal treatment. Reasons of increasing breast cancer incidence are discussed and historical overview

of hormonal treatment posibilities in pacients with breast cancer is summarized. The main part of the article characterizes influence of

tamoxifen into woman organism, especially in her genital tract (endometrium changes) and side effects are analysed. The retrospective

trial (Dept. Obst. and Gyn. 3-rd Medical Faculty) focusing pathological changes of endometrium under tamoxifen influence is mentioned.

Design of monitoring algorithm of breast cancer patients with intact uterus under treatment of tamoxifen is elaborated. Complications

and difficulties of this monitoring are specified. Another problem, controversial hormonal replacement therapy in breast cancer patients

suffered from climacteric syndrom is solved.

therapy.

Keywords: breast cancer, hormonal treatment, tamoxifen treatment complications, pathology of endometrium, hormonal replacement

Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bendová M. Hormonal treatment of breast cancer pacients from the viewpoint of the gynecologist. Onkologie. 2011;5(3):169-174.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Buzdar A, Chlebowski R, Cuzik J, et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 2006; 22(8): 1575-1585. Go to original source... Go to PubMed...
    2. Bouda J, Štěpán J, Svoboda T, et al. Sledování pacientek léčených tamoxifenem pro karcinom prsu. Praktická gynekologie 2006; 10(2): 60-63.
    3. Lech M, Ostrowska L. Risk of cancer development in relation to oral contraception. The European Journal of Contraception and Reproductive Health Care, September 2006; 11(3): 162-168. Go to original source... Go to PubMed...
    4. Ingle J, Dowsett M. Advances in Endokrine Therapy of Breast Cancer. Library of Congress Cataloging - in-Publication Data, Canada, 2004. Go to original source...
    5. Rayter Z, Mansi J. Medical Therapy of Breast Cancer, Cambridge University Press, 2003. Go to original source...
    6. Kult D, Svoboda B, Havránková A. Patologie endometria u postmenopauzálních pacientek s karcinomem prsu léčených tamoxifenem. Praktická gynekologie 2004; 3: 39-41.
    7. Ansbacher R, Advincula A. Endometrial polyp secondary to tamoxifen therapy. Fertility and Sterility 2003; 80(1): 216-217. Go to original source... Go to PubMed...
    8. Vosse M, Renard F, Coibion M, et al. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eupopean Journal of Obstetrics and Gynecology and Reproductive Biology 2002; 101: 58-63. Go to original source... Go to PubMed...
    9. Gerber B, Krause A, Muller H, et al. Effects of Adjuvant Tamoxifen on the Endometrium in Postmenopausal Women With Breast Cancer: A Prospective Long-Term Study Using Transvaginal Ultrasound. Journal of Clinical Oncology 2000; 18(20): 3464-3470. Go to original source... Go to PubMed...
    10. Andia D, Lafuente P, Matorras R, et al. Uterine side effects of teratment with tamoxifen. European Journal of Obstetrics and Gynecology and Reproductive Biology 2000; 92: 235-240. Go to original source... Go to PubMed...
    11. Žaloudík J. Aktuální témata hormonální regulace nádorového růstu. 6th International Congress on Hormones and Cancer, Jerusalem, Israel, 1999: 5-9.
    12. Juneja M, Jose R, Kekre AN, et al. Tamoxifen-induced endometrial changes in postmenopausal women with breast carcinoma. International Journal of Gynecology and Obstetrics 2002; 76: 279-284. Go to original source... Go to PubMed...
    13. Hann L, Gretz E, Bach A, et al. Sonohysterography for Evaluation of the Endometrium in Women Treated with Tamoxifen. American Journal of Radiology 2001; 177: 337-342. Go to original source... Go to PubMed...
    14. Marchesoni D, Driul L, Fabiani G, et al. Endometrial histologic changes in post-menopausal breast cancer patients using tamoxifen. International Journal of Gynecology and Obstetrics 2001; 75: 257-262. Go to original source... Go to PubMed...
    15. Donát J. Současný pohled na hormonální léčbu po menopauze. Klimakterická Medicina 2010; 1(15): 5-9.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.